艾迪注射液联合TPF化疗方案治疗中晚期宫颈癌患者的效果  

Effects of Aidi injection combined with TPF chemotherapy in treatment of patients with middle and middle and advanced cervical cancer

作　　者：潘学景 PAN Xuejing(Department of Obstetrics and Gynecology of Nanyang Central Hospital,Nanyang 473000 Henan,China)

机构地区：[1]南阳市中心医院妇产科,河南南阳473000

出　　处：《中国民康医学》2024年第23期87-90,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察艾迪注射液联合TPF(顺铂+紫杉醇+氟尿嘧啶)化疗方案治疗中晚期宫颈癌患者的效果。方法:回顾性分析2022年5月至2023年7月该院收治的68例中晚期宫颈癌患者的临床资料,按治疗方法不同将其分为对照组(n=34)与研究组(n=34)。对照组采用TPF化疗方案治疗,研究组在对照组基础上联合艾迪注射液治疗。比较两组疾病控制率,治疗前后细胞免疫功能指标[CD4^(+)/CD8^(+)、CD4^(+)、CD3^(+)、自然杀伤(NK)细胞]、血清肿瘤标志物[癌胚抗原相关细胞黏附因子6(CEACAM6)、鳞状细胞癌抗原(SCCA)、肿瘤特异性生长因子(TSGF)]水平,以及不良反应发生率。结果:研究组疾病控制率为91.18%(31/34),高于对照组的70.59%(24/34),差异有统计学意义(P<0.05);治疗后,两组NK细胞、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前,但研究组高于对照组,差异有统计学意义(P<0.05);两组CEACAM6、SCCA、TSGF水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组血小板减少、恶心/呕吐、肝/肾功能损伤、骨髓抑制等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:艾迪注射液联合TPF化疗方案治疗中晚期宫颈癌患者可提高疾病控制率和细胞免疫功能指标水平,以及降低肿瘤标志物水平的效果优于单纯TPF化疗方案治疗。Objective:To observe effects of Aidi injection combined with TPF(Cisplatin+Paclitaxel+Fluorouracil)chemotherapy in treatment of patients with middle and advanced cervical cancer.Methods:The clinical data of 68 patients with middle and advanced cervical cancer admitted to this hospital from May 2022 to July 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group(n=34)and study group(n=34).The control group was treated with TPF chemotherapy,while the study group was treated with Aidi injection on the basis of that of the control group.The disease control rate,the levels of cellular immune function indexes[CD4^(+)/CD8^(+),CD4^(+),CD3^(+),natural killer(NK)cells]and serum tumor markers[carcinoembryonic antigen-related cell adhesion factor 6(CEACAM6),squamous cell carcinoma antigen(SCCA),tumor specific growth factor(TSGF)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate of the study group was 91.18%(31/34),which was higher than 70.59%(24/34)of the control group,the difference was statistically significant(P<0.05).After the treatment,the levels of NK cells,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were lower than those before the treatment,but those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of CEACAM6,SCCA and TSGF in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as thrombocytopenia,nausea/vomiting,liver/kidney function injury,bone marrow suppression between the two groups(P>0.05).Conclusions:Aidi injection combined with TPF chemotherapy in the treatment of the patients with middle and advanced cervical cancer can improve the disease control rate and th

关 键 词：艾迪注射液 TPF化疗方案 中晚期 宫颈癌 疾病控制率 肿瘤标志物 细胞免疫 

分 类 号：R979.1[医药卫生—药品]